Original from: businesswire
Thermo Fisher Scientific Inc. (NYSE: TMO) (¡°Thermo Fisher¡±), the world leader in serving science, announced that its wholly owned subsidiary, Orion Acquisition AB (the ¡°Buyer¡±), has extended the expiration time of the offering period of its previously announced tender offer (the ¡°Offer") to acquire all of the outstanding common shares (¡°Shares¡±) and all of the outstanding American Depositary Shares, each representing one Share (¡°ADSs¡± and, together with the Shares, the ¡°Offer Securities¡±), of Olink Holding AB (publ) (¡°Olink¡±) for $26.00 per Share and per ADS, in cash.
The Offer is being made pursuant to the Purchase Agreement, dated as of October 17, 2023, by and between Thermo Fisher and Olink. The Offer is now scheduled to expire at 5:00 p.m., New York time, on December 14, 2023, unless the Offer is extended or earlier terminated.
DNB Markets, a part of DNB Bank ASA, Sweden Branch, the depositary and paying agent for the Offer with respect to the Shares, has advised Thermo Fisher and Buyer that, as of 6:00 p.m., New York time, on November 30, 2023, the last business day prior to the announcement of the extension of the Offer, approximately 84,597,461 Shares have been validly tendered and not properly withdrawn pursuant to the Offer. The Bank of New York Mellon, the tender agent for the Offer with respect to the ADSs, has advised Thermo Fisher and Buyer that, as of 6:00 p.m., New York time, on November 30, 2023, the last business day prior to the announcement of the extension of the Offer, approximately 33,835,892 ADSs have been validly tendered and not properly withdrawn pursuant to the Offer. These Shares and ADSs collectively represent approximately 95.2% of the outstanding Shares as of such time.
Olink shareholders who have already tendered their Shares or ADSs of Olink do not have to re-tender their Shares or ADSs or take any other action as a result of the extension of the expiration time of the Offer.
Completion of the Offer remains subject to the conditions described in the tender offer statement on Schedule TO, as amended and supplemented from time to time, filed by Thermo Fisher with the U.S. Securities and Exchange Commission on October 31, 2023.
